PHASE I STUDY OF O-6 BENZYLGUANINE AND CARMUSTINE IN ADVANCED CANCER

O-6 苄基鸟嘌呤和卡莫司汀治疗晚期癌症的 I 期研究

• 批准号: 6245581
• 负责人: RICHARD L SCHILSKY
• 金额: $ 3.72万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245581
• 关键词: alkyltransferase; antineoplastics; carmustine; clinical research; clinical trial phase I; dosage; drug screening /evaluation; enzyme activity; enzyme inhibitors; guanine analog; human subject; neoplasm /cancer; neoplasm /cancer chemotherapy; pharmacokinetics

Benzylguanine is a potent inactivator of alkylguanine transferase, a DNA repair protein that confers resistance to carmustine. This study will evaluate the pharmacokinetics of benzylguanine in man, the time course of alkylguanine trasnferase inhibition, the optimal dose of BG and the maximum dose of carmustine that can be safely administered with BG in patients with advanced cancer.

苄基鸟嘌呤是一种有效的烷基鸟嘌呤转移酶灭活剂， 能抵抗卡莫司汀的修复蛋白质。 本研究将 评价苄基鸟嘌呤在人体内的药代动力学， 烷基鸟嘌呤转移酶抑制剂，BG的最佳剂量和 与BG联合给药时可以安全使用的卡莫司汀最大剂量 晚期癌症患者。